BioDelivery Sciences International completes acquisition of Elyxyb for acute migraine treatment in the U.S. and Canada
BioDelivery Sciences International, Inc. a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced that it has completed the acquisition of U.S. and Canadian rights to Elyxyb (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.
Elyxyb is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. BDSI intends to launch Elyxyb in the first quarter of 2022. Additionally, BDSI plans to conduct an Elyxyb pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine attacks.